| |
| Clinical Trials |
BGP-15 has successfully completed a
"proof of concept" Phase II/a study. Results of the trial
are expected to be announced at the 66th Annual Scientific
Sessions conference of the American Diabetes Association,
June 9-13 in Washington, DC.
N-Gene's second lead compound, NG-SUN, is a photoprotection
and antiaging substance. NG-SUN completed four concomitant
human phase I studies in Hamburg, Germany. Currently the
anti-aging/photoprotection efficacy of NG-SUN was being
tested in a completed human phase II clinical trial in
France in a joint research collaboration with Dior, member
of the LVMH Group. |
| |
|
